Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. (Q50046367)

From Wikidata

Jump to navigation Jump to search

scientific article published on 9 February 2018

Language	Label	Description	Also known as
English	Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.	scientific article published on 9 February 2018

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

phase III clinical trial

0 references

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

Fabio Piscaglia

object named as

Fabio Piscaglia

6

0 references

1

object named as

Masatoshi Kudo

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

10

object named as

Jacek Jassem

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

5

object named as

Kenji Ikeda

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

16

object named as

Corina Dutcus

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

author name string

Richard S Finn

2

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

Shukui Qin

3

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

Kwang-Hyub Han

4

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

Ari Baron

7

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

Joong-Won Park

8

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

Guohong Han

9

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

Jean Frederic Blanc

11

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

Arndt Vogel

12

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

Dmitry Komov

13

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

T R Jeffry Evans

14

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

Carlos Lopez

15

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

Matthew Guo

17

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

Kenichi Saito

18

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

Silvija Kraljevic

19

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

Toshiyuki Tamai

20

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

Min Ren

21

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

Ann-Lii Cheng

22

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

language of work or name

0 references

publication date

9 February 2018

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatocellular carcinoma: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of hepatocellular carcinoma: An update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-lif

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2818%2930207-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(18)30207-1

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

release_aczd6kctrfelpayfwqtd5au64m

1 reference

https://api.fatcat.wiki/v0/release/aczd6kctrfelpayfwqtd5au64m

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 February 2018

http://europepmc.org/abstract/MED/29433850

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50046367&oldid=2119126352"